The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Diabetic macular edema: new concepts in patho-physiology and treatment
Open accessAbstract
Diabetic macular edema (DME), a serious eye complication caused primarily by hyperglycemia, is one of the major causes of blindness. DME, which is characterized by cystic retinal thickening or lipid deposition, is prone to relapse after successful treatment. DME is a complex pathological process caused by multiple factors, including breakdown of the inner and outer blood-retinal barriers, oxidative stress, and elevated levels of vascular endothelial growth factor which have been demonstrated in both preclinical and clinical studies. Starling's law theory explains many of the features of DME. Early detection and treatment of DME can prevent vision loss. Current effective interventions for DME include treatment of systemic risk factors, such as elevated blood glucose, blood pressure and dyslipidemia. Ophthalmic treatments include laser photocoagulation, surgery and intraocular pharmacotherapy. New drugs, which are given by intraocular injection, have emerged in recent years to become first line treatment for DME that affects the central macula with loss of vision. Laser photocoagulation is still the gold standard of treatment for DME which does not involve the central macular. This review outlines these new treatments with particular emphasis on the optimal timing of how they are given.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 2×
“It has been well accepted that FLK-1 is the principle mediator of VEGF-A’s effect on vascular permeability and angiogenesis [46].”
BackgroundGlobal prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985 · cited 2×
“According to the new meta analysis data in 2013, All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes [5].”
BackgroundMethodSelf-citationNormalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277 · cited 3×
“Hyperglycemia induces mitochondrial superoxide over-expression, and leads to the activation of the hexosamine pathway [67].”
BackgroundAntonetti, D. A., Klein, R., & Gardner, T. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1005073 · Cited by 1,659
Complex Phenotype of Mice Lacking Occludin, a Component of Tight Junction Strands
Saitou, M., Furuse, M., Sasaki, H., Schulzke, J.-D., Fromm, M., Takano, H., Noda, T., & Tsukita, S. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.12.4131 · Cited by 1,195 · cited 1×
“JAMs belong to the immunoglobulin super-family and are located close to tight junction strands [17,24].”
BackgroundHammes, H.-P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., et al. (2003) · Nature Medicine · doi:10.1038/nm834 · Cited by 785 · cited 1×
“Activation of this pathway has been found to induce oxidative stress [85], production of some pro-inflammatory cytokines such as TGF-α [67], −β [86] and plasminogen activator inhibitor [87], which subsequently induce diabetic retinal neuronal apoptosis [88], endothelial dysfunction [89] and BRB breakdown [90].”
BackgroundMelder, R. J., Koenig, G. C., Witwer, B. P., Safabakhsh, N., Munn, L. L., & Jain, R. K. (1996) · Nature Medicine · doi:10.1038/nm0996-992 · Cited by 451
Glucose, Advanced Glycation End Products, and Diabetes Complications: What Is New and What Works
Peppa, M., Uribarri, J., & Vlassara, H. (2003) · Clinical Diabetes · doi:10.2337/diaclin.21.4.186 · Cited by 234
Suzuma, K., Takahara, N., Suzuma, I., Isshiki, K., Ueki, K., Leitges, M., Aiello, L. P., & King, G. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022644499 · Cited by 170 · cited 1×
“The regulation of VEGF-A gene expression has been shown to be controlled and enhanced by PKC-β in a transgenic mouse model [66].”
BackgroundCameron, N. E., & Cotter, M. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118104 · Cited by 147
Cited by
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017) · JCI Insight · doi:10.1172/jci.insight.93751 · Cited by 1,057
“the blood-retinal barrier (BRB), with consequent vascular leakage of fluid and circulating proteins into the neural retina (3, 9, 10).”
BackgroundRole of Inflammation in Diabetic Retinopathy
Rübsam, A., Parikh, S., & Fort, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040942 · Cited by 750
“While for diabetes the breakdown of the inner blood retinal barrier (BRB) is believed to play a dominant role in vascular leakage [5,6], an important role of the outer BRB has recently gained momentum (for review [7]).”
BackgroundSchmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 703
Diabetic Retinopathy: Vascular and Inflammatory Disease
Semeraro, F., Cancarini, A., dell’Omo, R., Rezzola, S., Romano, M. R., & Costagliola, C. (2015) · Journal of Diabetes Research · doi:10.1155/2015/582060 · Cited by 424
Lipoprotein‐associated phospholipase A2: The story continues
Huang, F., Wang, K., & Shen, J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21597 · Cited by 212
“both the NPDR and PDR phases and is considered the clinical feature that is most strongly associated with vision loss.(189) Even though the pathology and molecular mechanism of DR are complicated, it is probably not only a vascular disease but also a neurodegenerative disease.”
Background
Metadata
- Authors
- Zhang, X., Zeng, H., Bao, S., Wang, N., & Gillies, M. C.
- Venue
- Cell & Bioscience
- Published
- 2014
- Volume
- 4
- Issue
- 1
- Pages
- 27
- ISSN
- 2045-3701 (ISSN-L)
- OpenAlex
- W2121435502
- Cited by
- 230
- References
- 10
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.